BNTX Q2 2025: US COVID vax at 20% may dent key vaccine revenue
- Strong COVID-19 Vaccine Business: Despite lower vaccination rates, management is confident in preserving its high market share (over 50% globally with Pfizer) and driving next‐generation and combination vaccine strategies, which supports ongoing revenue stability.
- Promising Oncology Pipeline: The Q&A highlighted encouraging Phase II data and planned Phase III trials—especially for BNT327 in both small cell and non‐small cell lung cancer—with benchmarks set against established studies, underlining the potential for improved clinical outcomes and market differentiation.
- Strategic Collaboration and Cost Sharing: The ongoing collaboration with BMS not only accelerates clinical development through shared R&D costs on a 50/50 basis but also paves the way for future milestone payments and a more robust oncology portfolio, supporting long‐term value creation.
- Lower COVID-19 Vaccination Rates: The Q&A highlighted that vaccination rates in the U.S. remain at about 20%, with expectations of a further slight drop. This lower uptake could pressure the COVID-19 vaccine revenue, which makes up a significant part of current earnings guidance [Ramón Zapata, Asad Haider, Q&A, index 14].
- Uncertainty in Clinical Trial Outcomes: There are open questions regarding the dosing strategy and the timing for top-line data releases for pivotal programs such as BNT327. The uncertainty around the Phase II/III data leaves execution and regulatory risks that may delay clinical milestones [Terence Flynn, Q&A, index 13].
- Regulatory Hurdles with Data Acceptance: Questions were raised about the acceptance of Chinese clinical data under the new FDA guidelines for certain assets, potentially complicating regulatory submissions for key trials. Any delay or increased scrutiny could adversely affect the timeline and approval of important programs [Akash Tewari, Q&A, index 14].
| Metric | Period | Previous Guidance | Current Guidance | Change |
|---|---|---|---|---|
Revenue | FY 2025 | EUR 1.7 billion to EUR 2.2 billion | €1.7 billion to €2.2 billion | no change |
R&D Expenses | FY 2025 | EUR 2.6 billion to EUR 2.8 billion | €2.6 billion to €2.8 billion | no change |
SG&A Expenses | FY 2025 | EUR 650 million to EUR 750 million | €650 million to €750 million | no change |
CapEx | FY 2025 | EUR 250 million to EUR 350 million | €250 million to €350 million | no change |
-
COVID & Collaboration
Q: Detail COVID revenue and Phase III acceleration?
A: Management noted that U.S. COVID vaccination rates remain low at around 20%, with revenues expected to phase in over the last 3–4 months. Coupled with the BMS deal, new Phase III trials are being evaluated under a 50-50 R&D cost-sharing model, and fixed-virus melanoma efficacy data will be presented at ESMO next year. -
Vaccine Strategy
Q: Why invest despite low vaccination rates?
A: Despite low uptake, management stressed that the robust global market share and plans for combination vaccines underpin the enduring value of their COVID franchise, justifying continued investment. -
Regulatory Data
Q: Will FDA accept Chinese trial data?
A: Management is finalizing discussions for three indications, integrating both Chinese and Western data, with an expectation to finalize Phase III dose selections within the next couple of weeks. -
Phase II Dosing
Q: What are BNT327 dosing details?
A: Details on dosing for both the small cell and non-small cell lung cancer Phase II trials will be disclosed soon, with top-line data anticipated at upcoming conferences, notably around September. -
Pipeline Timelines
Q: When are key pipeline data expected?
A: Management anticipates Phase II data for BNT327 this year, with registrational HER2 endometrial cohort data in early 2026 and INEST adjuvant colon cancer results by late 2025 or early 2026. -
Competitive Edge
Q: Is cooperative binding observed?
A: Management explained that BNT327’s mechanism is complex—its tumor microenvironment binding enhances VEGFA affinity synergistically. This differentiates it from Pfizer’s molecule, with more detailed data to be shared at an upcoming conference.
Research analysts covering BioNTech.